RBFC
CORT icon

Roman Butler Fullerton & Co’s Corcept Therapeutics CORT Stock Holding History

Roman Butler Fullerton & Co’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,354
Closed -$233K – 247
2025
Q1 		$233K Sell
3,354
-23,143
-87% -$1.41M 0.09% 193
2024
Q4 		$1.6M Buy
26,497
+20,932
+376% +$1.1M 0.51% 49
2024
Q3 		$261K Sell
5,565
-10,466
-65% -$372K 0.08% 214
2024
Q2 		$491K Buy
16,031
+6,757
+73% +$185K 0.16% 134
2024
Q1 		$207K Buy
+9,274
New +$219K 0.08% 207

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Roman Butler Fullerton & Co's CORT Position: Q2 2025 in Review

Roman Butler Fullerton & Co sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 3,354 shares — an estimated $233K sold.

Roman Butler Fullerton & Co first reported a position in CORT in Q1 2024 and held it in 5 quarters. The position peaked at $1.6M in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Roman Butler Fullerton & Co reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 3,354 Corcept Therapeutics shares in Q2 2025, an estimated $233K.
  • Roman Butler Fullerton & Co first reported a position in Corcept Therapeutics in Q1 2024 and held it in 5 quarters.
  • Roman Butler Fullerton & Co's Corcept Therapeutics position peaked at $1.6M in Q4 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2025, filed 30 Jul 2025.